- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04514497
Testing av tillegg av et kreftmedisin, BAY 1895344, til vanlig kjemoterapi for solide svulster i avansert stadium, med spesifikt fokus på pasienter med småcellet lungekreft, dårlig differensiert nevroendokrin kreft og bukspyttkjertelkreft
BAY 1895344 Plus Topoisomerase-1 (Top1)-hemmere hos pasienter med avanserte solide svulster, fase I-studier med ekspansjonskohorter i småcellet lungekarsinom (SCLC), dårlig differensiert nevroendokrint karsinom (PD-NEC) og pankreatisk adenocarcinom (PDA)
This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemotherapy (irinotecan or topotecan) in treating patients with solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), with a specific focus on small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding BAY 1895344 to irinotecan or topotecan may be safe and tolerable in treating patients with advanced solid tumors.
Studieoversikt
Status
Forhold
- Stadium III Bukspyttkjertelkreft AJCC v8
- Stage IV Bukspyttkjertelkreft AJCC v8
- Metastatisk bukspyttkjerteladenokarsinom
- Stadium III lungekreft AJCC v8
- Stadium IV lungekreft AJCC v8
- Ikke-opererbar ondartet fast neoplasma
- Metastatisk malignt fast neoplasma
- Uopererbart bukspyttkjerteladenokarsinom
- Metastatisk lunge småcellet karsinom
- Metastatisk nevroendokrint karsinom
- Ikke-opererbart småcellet lungekarsinom
- Ikke-opererbart nevroendokrint karsinom
Detaljert beskrivelse
PRIMARY OBJECTIVES:
I. To assess safety and tolerability of each of the elimusertib (BAY 1895344) plus topoisomerase 1 (top1) inhibitor (irinotecan hydrochloride [irinotecan] or topotecan hydrochloride [topotecan]) combinations.
II. To estimate maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of each of the combinations.
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity. II. To estimate objective response rate (ORR), progression free survival (PFS), overall survival (OS) and duration of response (DOR) in patients treated with each combination.
III. To estimate plasma pharmacokinetic (PK) characteristics of BAY 1895344 plus each top1 inhibitor (irinotecan or topotecan) when used in combination.
IV. To estimate changes in pharmacodynamic (PD) markers of deoxyribonucleic acid (DNA) damage (gamma-H2AX, phosphorylated [p]S343-NBS1) elicited by each combination from on-treatment tumor biopsies (in dose expansion cohorts only).
EXPLORATORY OBJECTIVES:
I. To estimate response outcomes (ORR, PFS, OS, DOR) in study patients by tumor ataxia telangiectasia mutated (ATM) expression loss (assessed by immunohistochemistry [IHC]).
II. To estimate response outcomes (ORR, PFS, OS, DOR) in study patients with tumor DNA damage response (DDR) mutations (assessed by whole exome sequencing [WES], ribonucleic acid [RNA] sequencing [RNA Seq], and circulating tumor DNA [ctDNA] analysis).
OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 3 cohorts.
COHORT I: Patients receive elimusertib orally (PO) twice daily (BID) on days 1 and 2 and irinotecan intravenously (IV) over 90 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) and/or magnetic resonance imaging (MRI) throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
COHORT II: Patients receive elimusertib PO once daily (QD) on days 2, 3, 9, 10, 16, and 17 of cycle 1 and 2, and on days 2, 3, 9, and 10 of each cycle thereafter. Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 of cycle 1 and 2, and on days 1 and 8 of each cycle thereafter. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
COHORT III: Patients receive elimusertib PO QD on days 2 and 5 and topotecan IV over 30 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening.
After completion of study treatment, patients are followed every 2 months for up to 6 months.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85054
- Mayo Clinic Hospital in Arizona
-
-
California
-
Orange, California, Forente stater, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06520
- Yale University
-
Trumbull, Connecticut, Forente stater, 06611
- Smilow Cancer Hospital Care Center-Trumbull
-
-
Florida
-
Jacksonville, Florida, Forente stater, 32224-9980
- Mayo Clinic in Florida
-
-
Kansas
-
Fairway, Kansas, Forente stater, 66205
- University of Kansas Clinical Research Center
-
Kansas City, Kansas, Forente stater, 66160
- University of Kansas Cancer Center
-
Overland Park, Kansas, Forente stater, 66210
- University of Kansas Cancer Center-Overland Park
-
Overland Park, Kansas, Forente stater, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Westwood, Kansas, Forente stater, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Forente stater, 55905
- Mayo Clinic in Rochester
-
-
Missouri
-
City of Saint Peters, Missouri, Forente stater, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Forente stater, 63141
- Siteman Cancer Center at West County Hospital
-
Kansas City, Missouri, Forente stater, 64154
- University of Kansas Cancer Center - North
-
Lee's Summit, Missouri, Forente stater, 64064
- University of Kansas Cancer Center - Lee's Summit
-
North Kansas City, Missouri, Forente stater, 64116
- University of Kansas Cancer Center at North Kansas City Hospital
-
St Louis, Missouri, Forente stater, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Forente stater, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Forente stater, 63136
- Siteman Cancer Center at Christian Hospital
-
-
New York
-
The Bronx, New York, Forente stater, 10461
- Montefiore Medical Center-Einstein Campus
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forente stater, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15232
- UPMC Hillman Cancer Center
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- DOSE ESCALATION COHORTS: Patients must have a biopsy-proven solid tumor that is metastatic or unresectable and has progressed on at least one line of standard therapy
- DOSE ESCALATION COHORTS: Patients must have a solid tumor for which irinotecan or topotecan is considered standard of care
- DOSE EXPANSION COHORTS: Patients must have biopsy proven metastatic or unresectable small cell lung cancer (SCLC), poorly differentiated neuroendocrine carcinoma (PD-NEC) (any extrapulmonary neuroendocrine carcinoma with small cell or large cell histology) or pancreatic adenocarcinoma (PDA) and have progressed on at least one line of standard therapy
- DOSE EXPANSION COHORTS: Patients must have at least one measurable lesion outside of the lesion to be biopsied
- Patients must be able to swallow pills
- Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with irinotecan or topotecan in patients < 18 years of age, children are excluded from this study
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Hemoglobin > 9 g/dL
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 2 x institutional upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN (=< 5 x institutional ULN if liver metastases present)
- Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression. Furthermore, these patients must be asymptomatic from previously treated brain metastases (e.g. not on steroids for neurologic symptoms within 30 days of study enrollment)
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- The effects of BAY 1895344 on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration
- Patient must have the ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients who have previously been treated with irinotecan will not be eligible to participate in the irinotecan arm and patients who have previously been treated with topotecan will not be eligible to participate in the topotecan arm. However, patients who previously received irinotecan may be treated with topotecan (and vice versa) should the other agent be considered a possible standard of care for their disease. Patients who have previously been treated with BAY 1895344 will be excluded from the study
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia and endocrinopathies from prior immunotherapy
- Patients who are receiving any other investigational agents
- The investigator(s) must state a medical or scientific reason if patients who have brain metastases will be excluded from the study
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study
- Patients receiving any medications or substances that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because BAY 1895344 is agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344, breastfeeding should be discontinued if the mother is treated with BAY 1895344. These potential risks may also apply to other agents used in this study
- Patients with an uncontrolled infection requiring IV antibiotics will not be eligible to participate in the study
- Patients on strong CYP3A4 inhibitors must discontinue them at least 1 week prior to starting irinotecan therapy
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort I (elimusertib, irinotecan)
Patients receive elimusertib PO BID on days 1 and 2 and irinotecan IV over 90 minutes on day 1 of each cycle. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo collection of blood samples
Andre navn:
Undergo tumor biopsy
Andre navn:
Given IV
Andre navn:
Given PO
Andre navn:
|
|
Eksperimentell: Cohort II (elimusertib, irinotecan)
Patients receive elimusertib PO QD on days 2, 3, 9, 10, 16, and 17 of cycle 1 and 2, and on days 2, 3, 9, and 10 of each cycle thereafter. Patients receive irinotecan IV over 90 minutes on days 1, 8, and 15 of cycle 1 and 2, and on days 1 and 8 of each cycle thereafter. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo collection of blood samples
Andre navn:
Undergo tumor biopsy
Andre navn:
Given IV
Andre navn:
Given PO
Andre navn:
|
|
Eksperimentell: Cohort III (elimusertib, topotecan)
Patients receive elimusertib PO QD on days 2 and 5 and topotecan IV over 30 minutes on days 1-5 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT and/or MRI throughout the study, tumor biopsy at screening and on study, and collection of blood samples at screening. |
Undergo CT
Andre navn:
Undergo MRI
Andre navn:
Undergo collection of blood samples
Andre navn:
Undergo tumor biopsy
Andre navn:
Given IV
Andre navn:
Given PO
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum Tolerated Dose (MTD) (Dose Escalation Phase) of Elimursertib
Tidsramme: Up to 21 days (first treatment cycle)
|
Defined by occurrence of >= 2 dose limiting toxicities (DLTs) defined as grade 4 neutropenia lasting >= 7 days, grade 4 thrombocytopenia, grade 4 anemia, grade 3 neutropenia with fever, grade 3 thrombocytopenia with bleeding, any grade 3 hematologic toxicity lasting >= 7 days (counting from first day of toxicity grade recognition) or any non-hematologic grade >= 2 adverse events (AEs) lasting >= 7 days (with the exception of grade 2 [G2] fatigue, G2 nausea or G2 diarrhea) (counting from first day of toxicity grade recognition) in any dose level during cycle 1 of treatment. DLTs will be graded by Common Terminology Criteria for Adverse Events version 5.0. |
Up to 21 days (first treatment cycle)
|
|
Maximum Tolerated Dose (MTD) (Dose Escalation Phase) of Irinotecan
Tidsramme: Up to 21 days (first treatment cycle)
|
Defined by occurrence of >= 2 dose limiting toxicities (DLTs) defined as grade 4 neutropenia lasting >= 7 days, grade 4 thrombocytopenia, grade 4 anemia, grade 3 neutropenia with fever, grade 3 thrombocytopenia with bleeding, any grade 3 hematologic toxicity lasting >= 7 days (counting from first day of toxicity grade recognition) or any non-hematologic grade >= 2 adverse events (AEs) lasting >= 7 days (with the exception of grade 2 [G2] fatigue, G2 nausea or G2 diarrhea) (counting from first day of toxicity grade recognition) in any dose level during cycle 1 of treatment. DLTs will be graded by Common Terminology Criteria for Adverse Events version 5.0. |
Up to 21 days (first treatment cycle)
|
|
Maximum Tolerated Dose (MTD) (Dose Escalation Phase) of Topotecan
Tidsramme: Up to 21 days (first treatment cycle)
|
Defined by occurrence of >= 2 dose limiting toxicities (DLTs) defined as grade 4 neutropenia lasting >= 7 days, grade 4 thrombocytopenia, grade 4 anemia, grade 3 neutropenia with fever, grade 3 thrombocytopenia with bleeding, any grade 3 hematologic toxicity lasting >= 7 days (counting from first day of toxicity grade recognition) or any non-hematologic grade >= 2 adverse events (AEs) lasting >= 7 days (with the exception of grade 2 [G2] fatigue, G2 nausea or G2 diarrhea) (counting from first day of toxicity grade recognition) in any dose level during cycle 1 of treatment. DLTs will be graded by Common Terminology Criteria for Adverse Events version 5.0. |
Up to 21 days (first treatment cycle)
|
|
Occurrence of Grade 4 Hematologic AEs (Dose Expansion Phase)
Tidsramme: Up to 6 months post-treatment
|
Grade 4 hematologic toxicity will be monitored using the Bayesian approach of Thall, Simon, Estey as extended by Thall and Sung. Clinical safety data (e.g. AEs) will be tabulated and summarized using descriptive statistics as requested by the sponsor investigator, executive committee, medical monitor or Data Safety Monitoring Board using methods described in the Data Safety Monitoring Plan. |
Up to 6 months post-treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR)
Tidsramme: Tumor response was performed every 6 weeks during treatment and up to 6 months after completing treatment
|
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT and/or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response Rate (ORR) = CR + PR. |
Tumor response was performed every 6 weeks during treatment and up to 6 months after completing treatment
|
|
Duration of Response (DOR)
Tidsramme: Response was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.
|
DOR will be estimated by the Kaplan-Meier method. Duration of response was calculated among patients with complete response, partial response, or stable disease. |
Response was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.
|
|
Progression-free Survival (PFS)
Tidsramme: Disease Progression was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.
|
PFS will be estimated by the Kaplan-Meier method. |
Disease Progression was assessed every 6 weeks while the patient was on treatment, and up to 6 months post-treatment.
|
|
Overall Survival (OS)
Tidsramme: From date the participant starts treatment until the date of death from any cause, assessed up to 6 months following completion of treatment
|
OS will be estimated by the Kaplan-Meier method. |
From date the participant starts treatment until the date of death from any cause, assessed up to 6 months following completion of treatment
|
|
Maximum Concentration (Cmax) of Elimusertib
Tidsramme: See above as time frames were different fore each dose cohort
|
Estimated for elimusertib based upon plasma collections from cycle 1 in all study patients. TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose; TACs 7,14: cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion |
See above as time frames were different fore each dose cohort
|
|
Area Under the Concentration-time Curve (AUC) for Elimusertib
Tidsramme: See above as time frames are different for each dose cohort
|
Will be estimated for elimusertib based upon plasma collections from cycle 1 in all study patients. TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose; TACs 7,14: cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion |
See above as time frames are different for each dose cohort
|
|
Maximum Concentration (Cmax) of Irinotecan (Cohorts I and II)
Tidsramme: See above as time frames were different for each cohort
|
Estimated for irinotecan based upon plasma collections from cycle 1 in all study patients. TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose |
See above as time frames were different for each cohort
|
|
Area Under the Concentration-time Curve (AUC) for Irinotecan
Tidsramme: See above as time frames were different for each cohort
|
Will be estimated for irinotecan based upon plasma collections from cycle 1 in all study patients. TACs 1,2: Before treatment, 30 min, 1h, 1.3h, 2h, 4h, 6h, 8h, 24h, and 48 h after first elimusertib dose; TACs 4,5: on Cycle 1 Day 1 Before treatment, 30 min, 1h, and 1.3h into infusion and 0.5h, 2.5h, 4.5h and 22h post end of infusion and Day 2 30 min, 1h, 1.3, 2h, 4h, 6h, 8h, 24h after the first elimursertib dose |
See above as time frames were different for each cohort
|
|
Maximum Concentration (Cmax) of Topotecan (Cohort III, TACs 7 and 14)
Tidsramme: Cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion
|
Estimated for topotecan based upon plasma collections from cycle 1 in all study patients. |
Cycle 1 day 1 and 2 before infusion, 5, 15, and 25 min into infusion, and 5, 15, 30 min, 1, 2, 4, 6, and 24 h post end of infusion
|
|
Area Under the Concentration-time Curve (AUC) for Topotecan
Tidsramme: Cycle 1
|
Will be estimated for topotecan based upon plasma collections from cycle 1 in all study patients. |
Cycle 1
|
|
Changes in Tumor Expression Patterns of Gamma-H2AX
Tidsramme: Baseline up to cycle 1, day 6
|
Will be estimated for expansion cohort only study patients. |
Baseline up to cycle 1, day 6
|
|
Changes in Tumor Expression Patterns of pS343-NBS1
Tidsramme: Baseline up to cycle 1, day 6
|
Will be estimated for expansion cohort only study patients. |
Baseline up to cycle 1, day 6
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Tumor ATM Expression Loss
Tidsramme: Baseline
|
Will assess the prevalence of tumor ATM expression loss in all patients. Will also estimate response outcomes (ORR, PFS, OS, DOR) in study patients by tumor ATM expression loss. |
Baseline
|
|
Tumor Deoxyribonucleic Acid Damage Response (DDR) Gene Mutations Present
Tidsramme: Baseline
|
Will assess the specific tumor DDR gene mutations present in study patients. Will also estimate response outcomes (ORR, PFS, OS, DOR) in study patients with tumors with DDR gene mutations. |
Baseline
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Thatcher Heumann, Yale University Cancer Center LAO
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Sykdommer i det endokrine systemet
- Patologiske prosesser
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Neoplasmer etter histologisk type
- Neoplasmer i fordøyelsessystemet
- Sykdommer i fordøyelsessystemet
- Lungesykdommer
- Neoplasmer i endokrine kjertel
- Pankreassykdommer
- Neoplasmer, kjertel og epitel
- Adenokarsinom
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Neoplastiske prosesser
- Karsinom
- Nevroektodermale svulster
- Neoplasmer, kjønnsceller og embryonale
- Neoplasmer, nervevev
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Nevroendokrine svulster
- Patologiske tilstander, tegn og symptomer
- Lungeneoplasmer
- Neoplasma Metastase
- Neoplasmer i bukspyttkjertelen
- Småcellet lungekarsinom
- Karsinom, nevroendokrine
- Heterocykliske forbindelser
- Undersøkelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og prosedyrer
- Diagnose
- Kirurgiske prosedyrer, operativ
- Cytologiske teknikker
- Cytodiagnose
- Camptothecin
- Alkaloider
- Diagnostiske teknikker, kirurgisk
- Kjemisteknikker, analytisk
- Spektrumanalyse
- Irinotekan
- Topotekan
- Biopsi
- Prøvehåndtering
- Magnetisk resonansspektroskopi
- Bay 1895344
Andre studie-ID-numre
- NCI-2020-05958
- UM1CA186689 (U.S. NIH-stipend/kontrakt)
- 10402 (Annen identifikator: CTEP)
- NCI-2020-05958 (Registeridentifikator: CTRP (Clinical Trial Reporting Program))
- 10402 (Annen identifikator: Yale University Cancer Center LAO)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .